Cell and gene therapy

#Cell and gene therapy #ELRIG #Events #Pharma

First ELRIG meeting on Cell & Gene Therapy

The ELRIG Cell & Gene Therapy meeting will be held virtually on May 18-19, 2021. This interactive two-day conference will host scientists from academia and industry to discuss current and future perspectives of cell and gene therapies. Cell and gene therapies are rapidly evolving, revealing many new therapeutic opportunities not… Read More

#News

#Biotechnology #Cell and gene therapy #Covid-19 #Drug delivery #Drug development #Drug technology #Immunology / Virology & Vaccines

Antibody therapeutics: the other race for immunity against SARS-CoV2

Sophie Lutter, OXGENE, looks at the important role antibody therapeutics have to play and how, as the world has looked for Covid-19 treatments in the last year, their significance has been noted. As the world continues to adjust and respond to the impact of the Covid-19 pandemic, the race to… Read More

#Covid-19 #Exclusive Content #News

#Cell and gene therapy #Clinical research #Drug development

Update on gene therapy trial where patient suffered loss of vision

Adverum Biotechnologies has announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its Infinity clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurred 30 weeks after randomisation in one patient treated with a single intravitreal… Read More

#News

#Biotechnology #Cell and gene therapy #Cell therapy #Genetics

Partnership to advance diversified gene therapy pipeline

Gene therapy company AavantiBio and Catalent, technologies, development, and manufacturing solutions service, have partnered to support the development and manufacturing of AavantiBio’s gene therapies, including Friedreich’s Ataxia (FA). Catalent will provide process development and CGMP manufacturing of AavantiBio’s adeno-associated viral (AAV) vector-based therapeutic candidate for use in clinical trials in the… Read More

#News

#Cell and gene therapy #Genetics #Genetics / genomics #Research

Genetic variants that impact immune cell functioning identified

New research has found that certain genetic variants that cause modified protein binding in immune cells are also seen in those at high risk of some autoimmune diseases. Scientists from the Wellcome Sanger Institute, Josep Carreras Leukaemia Research Institute in Spain, and the MRC London Institute of Medical Sciences (LMS)… Read More

#News

#Biotechnology #Cell and gene therapy #Cell therapy #Drug development #Drug discovery

ATMPS and Ori Biotech collaborate for cell and gene therapy developers

ATMPS, provider of blockchain-based “vein to vein” cell orchestration platforms for advanced therapies, and Ori Biotech, an innovator in cell and gene therapy (CGT) manufacturing platforms, have teamed up to create integration between their data platforms to support the development of advanced therapies. The partnership will result in the integration… Read More

#News

#Cancer research #Cell and gene therapy #Cell sequencing #DNA #Genetics

Scientists discover ‘jumping’ genes can protect against blood cancers

New research has uncovered an unexpected role for so-called “jumping” genes that are a source of genetic mutations responsible for many human diseases. In the new study from Children’s Medical Centre Research Institute at UT Southwestern (CRI), scientists discovered that these DNA sequences, also known as transposons, can protect against… Read More

#Cancer Research #News

#Cell and gene therapy #Drug delivery #Gene therapy #Life sciences

£18m network of gene therapy hubs to be created in the UK

LifeArc and the Medical Research Council (MRC), with support from the Biotechnology and Biological Sciences Research Council (BBSRC), have announced three major investments totalling £18 million to create a network of gene therapy innovation hubs. The funding will support the creation of three facilities to advance the clinical development of… Read More

#Editor's Choice #News

#Cell and gene therapy #Cell and Gene Therapy Catapult #Clinical trials

GSK expands trial manufacturing for cell and gene therapy

Cell and Gene Therapy Catapult (CGT Catapult) has announced that GSK will leverage the CGT Catapult Stevenage facility in the UK to perform GMP cell processing to accelerate its cell and gene therapy pipeline for clinical trials. Through this agreement, GSK will improve its GMP cell processing network to advance… Read More

#News

#Biotechnology #Cell and gene therapy #Pharmaceuticals

WuXi AppTec acquires OXGENE to strengthen cell and gene therapy service

WuXi AppTec, provider of R&D and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, has completed the acquisition of OXGENE, a UK-based contract research and development organisation that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the… Read More

#Editor's Choice #News

#ATMP #Cell and gene therapy #Cell and Gene Therapy Catapult #Clinical trials

Report cites UK as internationally attractive for development of cell and gene therapies

The Cell and Gene Therapy Catapult (CGT Catapult) has published today the 2020 Advanced Therapy Medicinal Product (ATMP) clinical trials database and report, which show a marked 20% growth in the number of ATMP clinical trials across the UK. The number of commercially sponsored trials has shown a dramatic surge… Read More

#Editor's Choice #News

#Biopharma #Cell and gene therapy

Rentschler Biopharma to build new cell and gene therapy capabilities in the UK

The Cell and Gene Therapy Catapult (CGT Catapult), an independent centre for advancing the UK’s cell and gene therapy industry, and Rentschler Biopharma, a global contract development and manufacturing organisation (CDMO) for biopharmaceuticals, have announced that Rentschler Biopharma will establish its manufacturing capability in Advanced Therapy Medicinal Products (ATMPs), including… Read More

#Editor's Choice #News

#Cell and gene therapy #Immunology / Virology & Vaccines #mRNA

Evonik strengthens strategic partnership with BioNTech on COVID-19 vaccine

Evonik is investing in the short-term expansion of its specialty lipids production which are essential for mRNA-based COVID-19 vaccines. Commercial lipid quantities are to be produced at Evonik’s Hanau and Dossenheim sites in Germany as early as the second half of 2021 as part of a strategic partnership with vaccine… Read More

#Covid-19 #Editor's Choice #News

#Cell and gene therapy #Covid-19

Akron Biotech agreement with Octapharma to produce virally inactivated human AB serum

Akron Biotechnology has signed an exclusive global agreement to manufacture virally inactivated human AB serum for the cell therapy market using Octaplas, Octapharma’s pooled, solvent-detergent treated human plasma. Akron Biotech is a manufacturer of cGMP-compliant ancillary materials for cell and gene therapy development and commercialisation. Switzerland-based Octapharma is one of… Read More

#News